Evidence Level
Omega-3 fish oil is among the most extensively studied supplements worldwide. The landmark REDUCE-IT trial (Bhatt et al., 2019) demonstrated that high-dose EPA (4g icosapent ethyl) reduced cardiovascular events by 25% in statin-treated patients with elevated triglycerides. For inflammation, a comprehensive meta-analysis by Li et al. (2019, 68 RCTs) confirmed significant reductions in CRP, IL-6, and TNF-alpha. The VITAL trial (Manson et al., 2019, n=25,871) found modest cancer risk reduction with 1g/day but no cardiovascular benefit at that low dose, underscoring that 2g+ daily is needed for anti-inflammatory effects. Mechanistically, EPA and DHA produce specialized pro-resolving mediators (resolvins, protectins) that actively resolve inflammation.
Recent studies have explored the benefits of omega-3 fish oil in various populations. Pruneti and Guidotti (2023) conducted a systematic review of six studies and found that oral supplementation with Omega-3, fish oil, and Vitamin D3 may improve depression symptoms in children, preadolescents, and adolescents. Minton et al. (2023) reported that fish oil with higher re-esterified triglyceride content resulted in greater incorporation into blood lipids compared to lower-content supplements in a randomized trial of 60 participants.
In maternal and child health, Sousa et al. (2023) conducted two randomized double-blind placebo-controlled trials involving 60 low-risk pregnant women each. The first study found no significant differences in child development between omega-3 and placebo groups but noted increased developmental milestones over time in the omega-3 group. The second study found no significant difference in maternal depressive symptoms between omega-3 and placebo groups from pregnancy to 6 months postpartum.
Overall, omega-3 fish oil has demonstrated cardiovascular benefits at high doses, anti-inflammatory effects, and potential mental health benefits in specific populations.